Dias Wickramanayake P, Klein H O, Pape S, Meyer-Hofmann H
Dtsch Med Wochenschr. 1985 Mar 29;110(13):487-91. doi: 10.1055/s-2008-1068850.
A new treatment protocol was developed for colorectal carcinomas consisting of sequential administration of methotrexate, 5-fluorouracil and cytarabine. The latter was included into the protocol in order to suppress the DNA salvage pathway of tumour cells. The sequential high-dosage combination was administered to 34 patients with metastatic colorectal carcinoma, 23 patients had been pretreated with cytostatics. Remission could be achieved in 14 out of the 34 patients. Two patients with carcinoma of the rectum have complete clinical remission lasting for 7 months. Eight of the 14 patients responding to treatment had had cytostatic pretreatment. The median time of survival of patients in remission is 15 months, median survival of non-responders 4,3 months. Combination treatment was well tolerated. Leuko- and thrombocytopenia according to grade 3 and 4 of the WHO classification were only rarely observed.
针对结直肠癌研发了一种新的治疗方案，该方案包括甲氨蝶呤、5-氟尿嘧啶和阿糖胞苷的序贯给药。将阿糖胞苷纳入该方案是为了抑制肿瘤细胞的DNA补救途径。这种序贯高剂量联合方案应用于34例转移性结直肠癌患者，其中23例患者此前接受过细胞抑制剂治疗。34例患者中有14例实现了缓解。两名直肠癌患者实现了持续7个月的完全临床缓解。14例对治疗有反应的患者中有8例此前接受过细胞抑制剂预处理。缓解患者的中位生存期为15个月，无反应者的中位生存期为4.3个月。联合治疗耐受性良好。仅很少观察到符合世界卫生组织3级和4级分类的白细胞减少和血小板减少。
